GlassScriptPhysician profile
Karen H Bruce
NPI 1942267281
$3,874.21
in general payments reported to CMS, 2019-2025
29 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $683 · 2021: $504 · 2022: $348 · 2023: $575 · 2024: $728 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $663.03 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $630.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $411.89 | 2019-2024 | |
| Lilly USA, LLC | $367.33 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $299.93 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $267.48 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $196.66 | 2019-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.38 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.31 | 2019-2024 | Trelegy Ellipta |
| Lexicon Pharmaceuticals, INC. | $66.81 | 2023-2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $65.46 | 2023-2024 | Nuedexta, Rexulti |
| Shield Therapeutics INC | $56.65 | 2023-2024 | Accrufer |
| Abbott Laboratories | $50.47 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $42.85 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.35 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.04 | 2025 | Caplyta |
| Medtronic, INC. | $39.56 | 2022-2025 | Intellis Adaptivestim |
| Amgen INC. | $38.41 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $35.11 | 2022-2024 | |
| Esperion Therapeutics, INC. | $35.08 | 2024-2025 | Nexletol |
| Lundbeck LLC | $35.05 | 2024 | Vyepti |
| Ibsa Pharma INC. | $33.50 | 2023-2024 | Tirosint, Licart, Licart |
| Novartis Pharmaceuticals Corporation | $28.65 | 2019 | |
| Allergan, INC. | $27.19 | 2020 | |
| Avanir Pharmaceuticals, INC. | $19.80 | 2022 | |
| Amarin Pharma, INC. | $18.38 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.00 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.